Asabys Partners — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
Deepull develops a multiplex PCR diagnostic system to rapidly identify sepsis-causing pathogens and antibiotic resistance markers directly from blood samples in approximately one hour, targeting hospitals and clinical laboratories.
Medical Devices
Co-investorsColumbus Venture Partners
Orikine Bio develops engineered cytokines called Foldikines™ to reprogram immune responses for treating autoimmune and inflammatory diseases.
BiotechDeep TechHealthtechMedical DevicesBarcelona, ES
Ariadna Montero(Scientific Founder, Head of Innovation Management & Corp. Comm.)inAlejo Chorny(Co-founder & Former-CEO)inProf. Luis Serrano(Scientific Founder, Advisor)Dr. Javier Delgado(Scientific Founder, Advisor)Christian Pangratz(CEO & Board Director)in
BoardLarry Edwards(Chairman of the Board)
Co-investorsAdBio partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Gradient Denervation Technologies
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.